NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

by · The Markets Daily

StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO – Free Report) in a research note issued to investors on Monday morning. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Performance

NASDAQ NURO opened at $3.97 on Monday. The company has a market cap of $8.11 million, a PE ratio of -0.86 and a beta of 2.18. NeuroMetrix has a 52-week low of $2.66 and a 52-week high of $4.73. The firm’s 50 day moving average price is $3.98 and its 200-day moving average price is $3.85.

NeuroMetrix (NASDAQ:NURO – Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share (EPS) for the quarter. The company had revenue of $0.59 million during the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. During the same quarter in the previous year, the company earned ($1.66) EPS.

NeuroMetrix Company Profile

(Get Free Report)

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.

See Also